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A B S T R A C T
Neuroendocrine tumors (NET) of the larynx are rare and heterogenous group, with much confusion about nature and
classification of these neoplasms in the past. Diagnosis is based primarily on light microscopy and confirmed by immu-
nohistochemistry and electron microscopy. A classification in 4 different types; paraganglioma, typical carcinoid, atypi-
cal carcinoid and small cell neuroendocrine carcinoma (SCNC) is a current consensus. Thorough diagnostic and a
proper classification of neuroendocrine neoplasms are of paramount importance – prognosis and treatment differ signifi-
cantly. We present two cases: 63-year old patient with SCNC of the larynx and a 53-year old patient with atypical car-
cinoid of the larynx. OctreoScan is useful tools for diagnostics and follow up of the patients and it is predictive for effec-
tiveness of octreotide therapy.
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Introduction
Laryngeal cancer accounts for approximately 2% and
5% of new malignancies worldwide every year, of which
85% to 90% are of the squamous type1,2. NET are rare in
the head and neck region, most commonly they originate
in the gastrointestinal system or the bronchial system:
the appendix, small intestine, rectum and bronchus3,4.
Within head and neck region, larynx is most commonly
NET involved site, in fact, NET are most common non-
-epidermoid larynx carcinoma type5. NET represent 0.5–
1% of larynx epithelial cancers6, and within larynx, they
occur more often in epiglottis and supraglottic region7.
First NET larynx case was described back in 1969 by
Goldman et al.8 and over 700 cases of this neoplasm have
been reported in literature since then9–12. Other NET
head and neck described sites include petrous apex, naso-
pharinx, tonsil, tongue, hypopharinx, salivary glands13–18.
NET of larynx are divided into 2 categories based on
their tissue of origin: epithelial and neural. Epithelial
category consists of 3 types: typical carcinoid (well differ-
entiated neuroendocrine carcinoma, grade I), atypical
carcinoid (moderately differentiated neuroendocrine car-
cinoma, grade II; large cell neuroendocrine carcinoma)
and small cell neuroendocrine carcinoma (poorly differ-
entiated neuroendocrine carcinoma, grade III). Neural
category consists of paraganglioma. NET of larynx are
also divided into primary and secondary types with the
latter being extremely rare. Only 5 cases of secondary
SCNC of larynx are reported in literature10 and differen-
tiation between primary lung and larynx SCNC is made
by imaging lung studies19. In this article, we describe two
cases of these rare neoplasms, summarize the current lit-
erature regarding NET and emphasize OctreoScan as
valid additional method for diagnostic and follow up of




A 63-yr-old man was referred to our center with
dispnea, dry cough and febrility up to 38 °C. He was pre-
viously, 2 months ago, treated in other hospital for leg
weakness and urine retention. Preliminary diagnostics
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showed L3 vertebra fracture, and the MR of the lumbal
spine and chest X-ray was performed. Laminectomy, re-
position and traspedicular biopsy was made and patho-
hystological report showed metastasis of SCNC. MSCT of
the thorax and upper abdomen was performed. We per-
formed fiberendoscopy which revealed a submucosal tu-
morous expansive mass on laryngeal side of epiglottis,
left ariepiglotic fold, left venricular fold with left cord fix-
ation (Figure 1). Clinical examination of the neck showed
bilaterally enlarged and fixated lymph nodes in reg. III. A
MSCT of the head and neck (Figure 2) showed an expan-
sive mass involving left side of the larynx, left side of the
epiglottis with possible infiltration, prominating in left
valecula, involving sinus piriformis, paralaryngeal space,
left vocal cord and anterior commisure reaching slightly
over the medial line. Infiltration and the destruction of
the left thyroid cartilage are seen, with possible left
cricoarythenoid joint destruction. Enlarged neck lymph
nodes on the left I region 12mm, II region 16mm right
II/III region 2 cm and VII region 14mm. Both jugular
veins are compressed and carotid arteries intact. We per-
formed laryngomicroscopy, biopsy and mapped the tumor.
Pathohistologic analysis showed carcinoma neuroendoc-
rines. A tumor is arising submucosally, but infiltrates ep-
ithelial surface focally. It is formed from monomorfic
small atypical cells forming sheets with hypercromatic
nuclei and scant cytoplasm (Figure 3), showing »crush-
ing« effect (Figure 4). Immunohistochemistry report
showed positive reaction on synapthophysin, AE1/AE3,
EMA and negative reaction on NSE and chromogranin.
Tumor stage (T4aN2Mx) was determined after clinical
and instrumental evaluation including CT scan. The pa-
tient subsequently underwent total laryngectomy with
left radical modified neck dissection (type I) and tracheo-
stomy formation (Figure 5). Postoperative pathohohisto-
logic report showed SCNC (carcinoma neuroendocrines
gr. III laryngis) with lymph nodes metastasis (reg. I 0,
reg. II 8/7, reg. III 2/2, reg. IV 0/0, reg. V 4/2). Following
such a ominous result of pathohistological analysis we
decided to treat contralateral neck and after 6 weeks we
performed right radical neck dissection. After the surgi-
cal treatment we performed an OctreoScan which was
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Fig. 1. Laryngoscopic image showing a tumorous mass involv-
ing laryngeal surface of epiglottis with left cord fixation.
Fig. 2. A MSCT scan showing expansive mass invading left side
of larynx, epiglottis, sinus piriformis, paralaryngeal space and
anterior commisure.
Fig.3. Small cell neuroendocrine carcinoma of the larynx. The
tumor is composed of uniform small cells with hypercromatic nu-
clei and scanty cytoplasm (H&E stain, original magnification,
x100).
Fig. 4. Small cell neuroendocrine carcinoma of the larynx. Tu-
mor cells with »crushing« effect (H&E stain, original magnifica-
tion, x200).
U:\coll-antropolo\coll-antro-(Suppl 2)-2012\05 Caric.vp
23. studeni 2012 15:49:29
Color profile: Disabled
Composite  150 lpi at 45 degrees
negative. Patient underwent chemotherapy treatment
with streptozocin and 5-FU. A patient died several
months after treatment.
Case 2 presentation
A 53-yr old patient was referred to our center with a
neck tumor progressing in size over a year, last few
months rapidly. Preliminary diagnostics was performed
in another hospital; neck and thyroid ultrasound show-
ing hipechogenic node in right thyroid lobe 42x21x24
mm in size and 2 enlarged lymphatic nodes in right III
neck region 31x20x18 mm and 32x29x15 mm. Scinti-
gram of the thyroid gland revealed »cold« zone in right
thyroid lobe. Citopunction of the reg.III node suggested
metastatic node from medullary thyroid carcinoma and
citopunction of the enlarged right thyroid lobe suggested
follicular thyroid tumor. Clinical status showed enlarged
right thyroid lobe and a neck mass in right III region. We
performed fiberendoscopy that revealed enlarged right
ariepiglottic fold (Figure 6).Operative treatment included
laryngomicroscopy with exscisional biopsy of the en-
larged right ariepiglottic fold, total thyreoidectomy with
selective right neck dissection (reg.II–IV) as well as pre-
tracheal and bilateral paratracheal dissection. Pathohis-
tologic report showed atypical carcinoid of the ariepiglot-
tic fold (Figure 7, 8) with metastasis to the reg. III of the
neck (Figure 9) as well as follicular adenoma of the right
thyroid lobe and microcarcinoma papillare of the left thy-
roid lobe without metastases to the paratracheal or pre-
tracheal region.A complication occurred a month after
an operation– formation of the neck abscess which war-
ranted neck exploration with drainage. A month later ad-
ditional resection of the right aryepiglotic fold from
petiolus to the right arytenoid was performed by CO2 la-
ser. Pathohistologic report showed small residual atypi-
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Fig. 5. Tumor involving supraglottic larynx, predominantly left
side with metastatic spread to the left side of neck.
Fig. 6. Tumorous mass involving right ariepiglottic fold.
Fig. 7. Submucosal laryngeal carcinoid arranged in trabecular
pattern with prominent fibrovascular stroma. (H&E stain, origi-
nal magnification, x400).
Fig. 8. Strong synaptophysin immunoreactivity in laryngeal car-
cinoid (original magnification, x400).
Fig. 9. Metastatic carcinoid in lymph node arranged in
solid sheets and nests (H&E stain, original magnification
x400).
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cal carcinoid tumor tissue next to the granulation tissue
and scar formed after the last excision. Residual tumor
tissue was completely exscised and removed with clear
pathohistologic margins. Patient has no symptoms to
present date and is waiting for OctreoScan to be per-
formed.
Discussion
The identification of NET is a stepwise process. Tu-
mor first should be recognized as neuroendocrine through
neuroendocrine morphology on conventional light micro-
scopy including peripheral palisading of tumor nests, tra-
beculae, glandular differentiation, rosette formation,
»crush artifact« and other histological features5. After
NET tumor consideration, it is important to distinguish
between subtypes, which is done by immunohistochemis-
try or electron microscopy. However, SCNC is predomi-
nantly a morphologic diagnosis, as in a limited number of
cases this tumor in negative for all neuroendocrine mar-
kers. In lungs absence of staining for neuroendocrine
markers occurs in 10–15%20. Immunohistochemistry does
not serve as a substitute but as a valid adjuvant in the
light evaluation of the morphologic criteria of these neo-
plasms21.Tumors of the larynx with neuroendocrine dif-
ferentiation have widely varying prognosis and response
to therapy – accurate histological diagnosis is essential.
NET can be confused with other neoplasms such as
adenocarcinoma, acinic cell carcinoma, basaloid squa-
mous cell carcinoma, solid type of adenoid cystic carci-
noma, poorly differentiated squamous cell carcinoma,
undifferentiated carcinoma, amelanotic malignant mela-
noma, medullar thyroid carcinoma, lymphoma, heman-
giopericytoma and others22. NET, or SCNC in particular,
presenting initially in larynx may be metastases from
distant sites. Most often primary site is the lungs, but
extrapulmonary sites have been reported23,24. Another
specific clinical feature of SCNC of the larynx is it's possi-
ble association with different paraneoplastic syndromes,
and this may be a reason for presentation10. Syndrome of
inappropriate secretion of antidiuretic hormone (SIADH),
myastenic syndrome, ectopic adrenocorticotropic hormone
(ACTH) syndrome have all been described25–27. Possible
symptoms include headache, confusion, temporo-spatial
disorientation, hyperreflexia, hyponatremia, reduced he-
matocrit, high plasma levels of antidiuretic hormone.
Atypical carcinoid is the most common neuroendocrine
tumor of the larynx28. It is more common among older
men (6th decade) with a history of heavy cigarette smok-
ing. The vast majority of this tumor shows a supraglottic
origin29. The diagnosis of atypical carcinoid may be diffi-
cult, especially on the initial biopsy evaluation but it is
crucial to make a proper diagnosis. In contrast with typi-
cal carcinoid mitosis, cellular pleomorphism and necrosis
are the critical features for diagnosis28. Immunohisto-
chemical staining is important additional tool in diag-
nostic process; carcinoma cells are usually positive for
markers such as chromogranin, synaptophysin, keratin,
calcitonin and carcinoembryonic antigen. The final diag-
nosis should not be based solely on the presence or ab-
sence of a single immunohistochemical stain marker, and
a panel of immunohistochemical antibodies is utilized29–31.
Another important diagnostic tool is OctreoScan, which
is used as help in diagnostics and follow up of the NET
patients. It is an Indium-111 labeled somatostatin analog
with high affinity for somatostatin receptors, which are
found on most NET tumors. It`s major advance is longer
biological half-life, and major benefit inhibition of hor-
mone secretion and, possible, tumor growth inhibition.
Octreotide, like somatostatin, binds to receptors on the
cells of carcinoid tumors and inhibits the manufacture
and release of tumor hormones. Octreotide is very effec-
tive in controlling the symptoms of flushing and diarrhea
that are part of the carcinoid syndrome. Octreotide has
been found to reduce the excretion of 5-HIAA in some pa-
tients. Octreotide also has been found to slow the growth
of carcinoid tumors, and, in a few patients, even reduce
the size of the tumors and their metastases. Positive
OctreoScan invocates octreotide therapy, which offers
additional hope for selected NET patients.
Treatment and prognosis Typical Carcinoid
These very rare tumors are best treated with conser-
vative surgery32,33, most often partial laryngectomy.
Larger tumors may require total laryngectomy, and neck
dissection is not indicated in view of the usual absence of
lymph node metastases30. Irradiation and chemotherapy
are not recommended as they are found to be ineffec-
tive12. However, metastases from this tumor have been
described, including distant and multiple liver meta-
stases34–36. Prognosis is not as favorable as we thought in
the past – 5-year survival rate is 48.7% in a large series37,
but it is unclear and doubtful that some of the typical
carcinoids have been misdiagnosed as atypical carcino-
ids12.
Atypical Carcinoid Tumor
Surgical excision is the treatment of choice12,32. As
many tumors are supraglottic, partial supraglottic la-
ryngectomy is often performed, but depending on the ex-
tent of the primary tumor, a total laryngectomy may be
warranted. As perineural extension may exist peripheral
to the tumor mass, wide resection beyond clinically de-
tectable cancer margins is indicated 38. Endoscopic laser
surgery is often employed instead of external approach
for supraglottic atypical carcinoid tumor39. Elective neck
dissection is warranted in view of the high incidence of
the early cervical metastases and subsequent involve-
ment of cervical nodes30,40. Although this tumor is re-
ported to be radiotherapy and chemotherapy resistant38,40,
addition of radiotherapy appears to be beneficial to at
least some patients as showed in a Gillenwater et al.29
retrospective study. Radiation therapy is recommended
for cases of local extension, multiple nodal metastases or
extracapsular disease31,41. Prognosis of this tumor is un-
favorable with aggressive behavior and high metastatic
potential. Cervical metastases are often present, and dis-
tant metastases to bone, skin, subcutaneous tissues, dis-
tant lymph nodes, lung, mediastinum, liver, heart, pan-
creas, diaphragm, peritoneum gastrointestinal tract,
prostate, breast, brain, dura mater, pleura testicle and
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muscle are also described. Death usually results from
distant metastases and not from the local or regional re-
currence. The survival rate is 48% at 5 years, and 30% at
10 years42.
Small Cell Neuroendocrine Carcinoma
Treatment is still a subject of debate, and role of a
radical surgery is yet to be fully evaluated. Although rad-
ical surgical procedures such as total laryngectomy and
radical neck dissection offer locoregional control of the
disease long term survival depends on the extent of the
disease43. It is wise and recommendable to perform a full
medical evaluation and systematic work-up to exclude
metastatic lung or extrapulmonary disease, as well as to
establish exact stage of the disease. The combination of
primary radiation therapy and adjuvant chemotherapy
resulted to prolonged median patient survival up to 55
months and is suggested by Baugh et al44. A combination
of cyclophosphamide, doxorubicin, vincristine, metho-
trexate and lomustine and a 9 to 18 month long treat-
ment is usually recommended44,45. SCNC generally has a
dismal prognosis, which depends on the extent of the dis-
ease. The 2 and 5 years survival rates are 16% and 5%,
respectively46. Different paraneoplastic syndromes have
been reported in cases of SCNC and reportedly all pa-
tients died47.
Paraganglioma
Partial laryngectomy remains the mainstay of treat-
ment of this benign lesions48. Transoral laser microsur-
gery is not recommended because of vascular nature of
these tumors. Preoperative angiography and emboliza-
tion are often unnecessary because of the generally small
size and consistent blood supply of the lesion. Ligation of
the arterial blood supply at the time of surgery will mini-
mize blood loss. Conservative procedures such as supra-
glottic laryngectomy or local excision via laryngofissure,
with or without cricoid split in small number of trans-
ventricular or infraglottic tumors are usually performed
and usually succesfull49–53. Behavior of this lesion is be-
nign and the prognosis is excellent with just one para-
ganglioma in literature accepted to have metastatic
spread54,55.
Conclusion
NET of larynx constitute a variety of rare neoplasms.
Many different names and classifications have been used
in the past, adding much to the confusion. Currently
NET of larynx are classified as typical carcinoid, atypical
carcinoid, SCNC and paraganglioma. It is of utmost im-
portance to make a proper diagnosis of NET subtype as
the treatment and prognosis differ. Larynx is the most
common extrapulmonary site of SCNC, with only 5 cases
of secondary SCNC to the larynx described in litera-
ture10, and differentiation is made by imaging studies19.
SCNC is also associated with different paraneoplastic
syndromes, and overall prognosis is bad. It is an aggres-
sive neoplasm often disseminated at presentation, and
extent of the disease is the most significant prognostic
factor for survival. Adding the concurrent chemoradio-
therapy offers potential for long-term survival. Atypical
carcinoid is tumor with aggressive behavior, high meta-
static potential and 30% 10-yr survival rate. It is best
treated by partial or total laryngectomy with elective or
therapeutic neck dissection. Adjuvant chemo/radiother-
apy could be beneficial, at least for some patients. Oc-
treoScan is valid additional test in diagnosis and follow
up of the NET patients, and octreotide therapy offers
hope for higher and prolonged survival.
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NEUROENDOKRINI TUMORI LARINKSA – PRIKAZ DVA SLU^AJA I PREGLED LITERATURE
S A @ E T A K
Neuroendokrini tumori larinksa rijetka su i heterogena grupa neoplazmi o ~ijoj prirodi i podjeli je u pro{losti bilo
dosta proturje~ja. Dijagnoza bolesti postavlja se primarno svjetlosnom mikroskopijom, a potvr|uje imunohistokemijom
i elektronskommikroskopijom. Suvremeni konsenzus je podjela neuroendokrinih tumora na 4 tipa: paragangliom, tipi-
~ni karcinoid, atipi~ni karcinoid i karcinommalih stanica. Precizna dijagnostika i klasifikacija neuroendokrinih tumora
od najve}e je va`nosti – prognoza i na~in lije~enja uvelike se razlikuju. Predstavljamo dva slu~aja: 63-godi{njeg boles-
nika sa karcinomom malih stanica i 53-godi{njeg bolesnika sa atipi~nim karcinoidom larinksa. Oktreosken je va`an za
dijagnostiku i pra}enje bolesnika te prediktivan za efikasnost terapije oktreotidom.
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